Hogan Lovells Podcasts
Podcast: Talking the cure
24 October 2022
Senior DirectorWashington, D.C.
Email [email protected]hoganlovells.com
Phone +1 202 637 5459
Fax +1 202 637 5910
Practice groupGlobal Regulatory
Susan Tiedy-Stevenson assists clients in obtaining FDA marketing approvals and clearances for diagnostic tests and medical devices. She works with clients throughout the life cycle of product development in assessing FDA quality system requirements, clinical and analytical development, and implementation of post-marketing strategies. Susan is attuned to the needs of large corporations and start-up companies in formulating practical solutions to address FDA regulatory requirements.
She has deep insight into the FDA's biologics and medical device regulation of in vitro diagnostics (IVD) assays and related instruments, accessories, laboratory developed tests, and drug companion diagnostics. Susan also assists clients concerning FDA regulation of non-IVD medical devices including, in part, diabetes diagnostic and treatment devices and standalone software diagnostic applications.
Previously, Susan held executive management positions in regulatory, clinical, and quality for IVD, medical device, and biologic product companies and was responsible for preclinical and clinical study programs, development of regulatory strategies and premarketing submissions to the FDA and international authorities, and establishment and monitoring of good manufacturing practice programs compliant with FDA regulations.
Education
M.S., Central Michigan University, 1979
Graduate Studies, University of Pittsburgh, 1974
B.S., Chatham College, 1972
Memberships
AMDM Companion Diagnostics Working Group
Regulatory Affairs Professional Society
Obtained the first HPV test for cervical cancer and continued to secure additional FDA approvals for HPV assays *
Secured the FDA's first ever Clinical Laboratory Improvement Amendments (CLIA) waiver approval for doctor office syphilis testing.
Obtained PMA approval and 510(k) clearances for a variety of medical devices.
Trained companies and entrepreneurs on FDA premarketing and CLIA waiver submission requirements.
*Matter handled prior to joining Hogan Lovells.
Hogan Lovells Podcasts
24 October 2022
Insights and Analysis
Registered Content
31 May 2022
News
22 November 2021
Press Releases
14 April 2021
News
24 February 2021
Press Releases
18 December 2020